We are thrilled to announce the launch of our brand new website: www.luminarygroup.co.uk Luminary Group, is an international executive search and business consultancy specializing in the Life Sciences and Pharmaceutical sectors. Contact us today! #NewWebsite #LuminaryGroup #DigitalLaunch #ExploreNow
About us
Luminary Group is a international business consultancy focused on the life sciences and pharmaceutical sectors. Headquartered at St Magnus House, 3 Lower Thames Street, Central London, EC3R 6HD, we deliver comprehensive services in three key areas. Luminary Executive: Specializing in C-suite to Director-level appointments, we identify top talent for positions including Chairman, Board members, CEO, CCO, COO, AVP to Director level. Luminary Staffing: We provide both temporary and permanent staffing solutions tailored to meet the commercial, project management, medical, biometrics, software and operational needs of our clients. Luminary Consulting: Offering high-quality services in medical writing, regulatory affairs, quality assurance, pharmacovigilance, and data science for the medical and pharmaceutical industries. We also provide strategic partnerships to accelerate growth through Recruitment Process Outsourcing (RPO) and Functional Service Provider (FSP) services. Lastly, our advisory services assist in data partnerships, leveraging our extensive network of leading RWE, RWD, and AI enterprises across the US and Europe, and provide guidance for business collaborations with biotechnology firms and navigating mergers and acquisitions. Our expertise includes Real World Evidence (RWE), eClinical solutions, Artificial Intelligence (AI), Biotechnology, Consulting, and Medical Devices. Operating globally with a presence in the USA, Europe, APAC, and the Middle East, we take pride in our exclusive talent pool, ranging from C-Suite to Managerial levels, and our partnerships with returning clients and candidates. Our collaborations extend across a diverse range of companies, from corporate giants to innovative start-ups. For more information, please visit our website: www.luminarygroup.co.uk.
- Website
-
www.luminarygroup.co.uk
External link for Luminary Group
- Industry
- Business Consulting and Services
- Company size
- 11-50 employees
- Headquarters
- City of London
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Executive Search, Headhunting, Consulting, Life Sciences, Pharmacovigilence, Regulatory Affairs, CMC, Biotechnology, Diagnostics, CRO, Clinical Trials, Cell & Gene Therapy, Machine Learning, Real World Evidence, Real World Data, eClinical, eCOA, RPO, FSP, Corporate Development, Partnerships, Data Partnerships, RWE, RWD, and Artificial Intelligence
Locations
-
Primary
Get directions
City of London , GB
-
Get directions
4th St N, STE 300
7901
St. Petersburg, FL , 33702, US
Employees at Luminary Group
Updates
-
𝗙𝗗𝗔 𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝘀 𝗿𝗲𝗳𝗼𝗿𝗺𝘂𝗹𝗮𝘁𝗲𝗱 𝗖𝗼𝘃𝗶𝗱 𝗯𝗼𝗼𝘀𝘁𝗲𝗿𝘀 𝗳𝗼𝗿 𝗳𝗮𝗹𝗹 𝘀𝗲𝗮𝘀𝗼𝗻 The FDA cleared a new round of Covid-19 boosters from Moderna and Pfizer that this time target the KP.2 variant. https://lnkd.in/dJ__Fi9T
-
𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗕𝗶𝗰𝗮𝗿𝗮 𝘂𝗻𝘃𝗲𝗶𝗹𝘀 𝗜𝗣𝗢 𝗽𝗶𝘁𝗰𝗵 𝘀𝗮𝗺𝗲 𝗱𝗮𝘆 𝗮𝘀 𝗭𝗲𝗻𝗮𝘀 For a while, there were none. Suddenly, there were two. Bicara Therapeutics filed Thursday afternoon for an initial public offering, just …Claire Mazumdar https://lnkd.in/dDKruzmZ
Oncology biotech Bicara unveils IPO pitch same day as Zenas
endpts.com
-
𝗔𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗭𝗲𝗻𝗮𝘀 𝗳𝗶𝗹𝗲𝘀 𝗳𝗼𝗿 𝗜𝗣𝗢 𝗮𝗺𝗶𝗱 𝘀𝘂𝗺𝗺𝗲𝗿 𝗹𝘂𝗹𝗹 𝗳𝗼𝗿 𝗽𝘂𝗯𝗹𝗶𝗰 𝗱𝗲𝗯𝘂𝘁𝘀 Zenas BioPharma filed for an initial public offering on Thursday, marking a rare move for biotech startups this summer. Lonnie Moulder https://lnkd.in/d7iQT2vs
Autoimmune biotech Zenas files for IPO amid summer lull for public debuts
endpts.com
-
𝗙𝗧𝗖 𝗯𝗮𝗰𝗸𝘀 𝗙𝗗𝗔 𝗽𝗹𝗮𝗻 𝘁𝗼 𝗿𝗲𝗺𝗼𝘃𝗲 𝘀𝘄𝗶𝘁𝗰𝗵𝗶𝗻𝗴 𝘀𝘁𝘂𝗱𝘆 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁 𝗳𝗼𝗿 𝗶𝗻𝘁𝗲𝗿𝗰𝗵𝗮𝗻𝗴𝗲𝗮𝗯𝗹𝗲 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 The Federal Trade Commission is backing a recent FDA proposal to officially remove the requirement that biosimilar developers must run switching studies to obtain interchangeability … https://lnkd.in/ddYGCM8A
FTC backs FDA plan to remove switching study requirement for interchangeable biosimilars
endpts.com
-
𝗩𝗲𝗿𝘀𝗮𝗻𝘁 𝗮𝗻𝗱 𝗡𝗼𝘃𝗮𝗿𝘁𝗶𝘀 𝗯𝘂𝗶𝗹𝗱 '𝗖𝗵𝗶𝗻𝗼𝗼𝗸 𝟮.𝟬' 𝗳𝗼𝗿 𝗥𝗡𝗔 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗶𝗻 𝗸𝗶𝗱𝗻𝗲𝘆 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀 Five years to the day after launching Chinook Therapeutics, a Novartis Company, Versant Ventures is back with a second generation of that kidney disease biotech … https://lnkd.in/dskqqFH9
Versant and Novartis build 'Chinook 2.0' for RNA therapies in kidney diseases
endpts.com
-
A glowing testimonial for our Partner at Luminary Group, Ted Smith-Carey... "Ted was an absolute pleasure to work with; his proactive, honest, and collaborative approach made every aspect of the recruitment process significantly smoother. Ted's excellent communication skills and deep industry knowledge in Regulatory Affairs, Pharmacovigilance, and Quality Assurance ensured that we found the perfect fit for future roles. If you're looking for a transparent, intelligent, and efficient process when seeking new candidates or your next role, I highly recommend working with Ted!" Business Development Director - UK & Ireland Top 3 Life Sciences Consultancy Reach out to Ted for top-tier commercial opportunities in Regulatory Affairs, Pharmacovigilance, and Quality Assurance! #regulatoryaffairs #pharmacovigilance #qualityassurance #lifesciences #recruitment #talentacquisition
-
𝗕𝗶𝗼𝗠𝗮𝗿𝗶𝗻 𝘀𝗵𝗮𝗸𝗲𝘀 𝘂𝗽 𝗲𝘅𝗲𝗰𝘂𝘁𝗶𝘃𝗲 𝘁𝗲𝗮𝗺, 𝘁𝗮𝗽𝗽𝗶𝗻𝗴 𝗻𝗼𝘁𝗮𝗯𝗹𝗲 𝗱𝗲𝗮𝗹𝗺𝗮𝗸𝗲𝗿 𝗝𝗮𝗺𝗲𝘀 𝗦𝗮𝗯𝗿𝘆 BioMarin Pharmaceutical Inc. is bringing prominent dealmaker James Sabry onto its executive team, along with Amgen rare disease veteran Gregory Friberg https://lnkd.in/dJp65RFd
BioMarin shakes up executive team, tapping notable dealmaker James Sabry
endpts.com
-
𝗕𝗿𝗶𝗱𝗴𝗲𝗕𝗶𝗼 𝗳𝗼𝗿𝗺𝘀 𝗮𝗻𝗼𝘁𝗵𝗲𝗿 𝗼𝗳𝗳𝘀𝗵𝗼𝗼𝘁 𝘄𝗶𝘁𝗵 $𝟯𝟬𝟬𝗠 𝗶𝗻 𝗰𝗼𝗺𝗺𝗶𝘁𝗺𝗲𝗻𝘁𝘀 BridgeBio is again offloading pieces of its pipeline as it stares down a November drug approval decision that could spark competition with …Neil Kumar https://lnkd.in/dS5y6YCY
BridgeBio forms another offshoot with $300M in commitments
endpts.com
-
𝗝&𝗝 𝘀𝗰𝗼𝗿𝗲𝘀 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗳𝗼𝗿 𝗥𝘆𝗯𝗿𝗲𝘃𝗮𝗻𝘁 𝗰𝗼𝗺𝗯𝗼 𝗶𝗻 𝗳𝗶𝗿𝘀𝘁-𝗹𝗶𝗻𝗲 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 Johnson & Johnson scored a label expansion for Rybrevant in combination with the newly-approved Lazcluze to treat certain first-line lung cancer patients, putting it in … https://lnkd.in/dJekaApZ
J&J scores approval for Rybrevant combo in first-line lung cancer, stoking rivalry with Tagrisso
endpts.com